The TAg-RB Murine Retinoblastoma Cell of Origin Has Immunohistochemical Features of Differentiated Müller Glia with Progenitor Properties by Pajovic, Sanja et al.
The TAg-RB Murine Retinoblastoma Cell of Origin Has
Immunohistochemical Features of Differentiated Mu¨ller
Glia with Progenitor Properties
Sanja Pajovic,1,2 Timothy W. Corson,2,3,4 Clarellen Spencer,1 Helen Dimaras,1,5,6,7
Marija Orlic-Milacic,1,5,6 Mellone N. Marchong,1,6,8 Kwong-Him To,1,5,6 Brigitte The´riault,1
Mark Auspitz,1 and Brenda L. Gallie1,5,6,8
PURPOSE. Human retinoblastoma arises from an undefined de-
veloping retinal cell after inactivation of RB1. This is emulated
in a murine retinoblastoma model by inactivation of pRB by
retinal-specific expression of simian virus 40 large T-antigen
(TAg-RB). Some mutational events after RB1 loss in humans are
recapitulated at the expression level in TAg-RB, supporting
preclinical evidence that this model is useful for comparative
studies between mouse and human. Here, the characteristics of
the TAg-RB cell of origin are defined.
METHODS. TAg-RB mice were killed at ages from embryonic day
(E)18 to postnatal day (P)35. Tumors were analyzed by immu-
nostaining, DNA copy number PCR, or real-time quantitative
RT-PCR for TAg protein, retinal cell type markers, and retino-
blastoma-relevant genes.
RESULTS. TAg expression began at P8 in a row of inner nuclear
layer cells that increased in number through P21 to P28, when
clusters reminiscent of small tumors emerged from cells that
escaped a wave of apoptosis. Early TAg-expressing cells coex-
pressed the developmental marker Chx10 and glial markers
CRALBP, clusterin, and carbonic anhydrase II (Car2), but not
TuJ1, an early neuronal marker. Emerging tumors retained
expression of only Chx10 and carbonic anhydrase II. As with
human retinoblastoma, TAg-RB tumors showed decreased
Cdh11 DNA copy number and gain of Kif14 and Mycn. It was
confirmed that TAg-RB tumors lose expression of tumor sup-
pressor cadherin-11 and overexpress oncogenes Kif14, Dek,
and E2f3.
CONCLUSIONS. TAg-RB tumors displayed molecular similarity to
human retinoblastoma and origin in a cell with features of
differentiated Mu¨ller glia with progenitor properties. (Invest
Ophthalmol Vis Sci. 2011;52:7618–7624) DOI:10.1167/iovs.11-
7989
The pediatric intraocular tumor retinoblastoma is initiatedby loss of the prototypic tumor suppressor RB1, which
encodes the cell cycle regulator pRB.1 However, the specific
cell type(s) in the developing human retina dependent on pRB
to suppress tumor development remains unknown. The prop-
erties of this extremely cancer-susceptible cell are important to
understand not only for retinoblastoma but also cancer initia-
tion in general.
Knowledge of the molecular mechanisms responsible for
progression of retinoblastoma after RB1 loss has come from
retinoblastoma mouse models. Complete knockout of Rb1 in
mice is embryonically lethal.2–5 Conditional inactivation of Rb1
and inactivation of additional pRB family members (p107 or
p130) are necessary for retinoblastoma development in
mice.6–8 Several murine retinoblastoma models use early reti-
nal gene promoters that direct conditional Rb1 inactivation in
a subset of retinal cells, combined with constitutional inactiva-
tion of p107 or p130. Such approaches have created retino-
blastoma models with tumors displaying amacrine and glial cell
characteristics.7–9 In each of these models, the specific cell
populations affected by Rb1 loss varies and many more cells
are rendered Rb1/ than in human disease, where the loss of
both RB1 alleles is a stochastic event in presumably relatively
few developing retinal cells.
The simian virus 40 large T antigen (TAg) provides a bio-
chemical means of functionally knocking out pRB family mem-
bers, along with p53 and other protein targets, and has been
used in various mouse tumor models.10 One planned mouse
pituitary tumor model was designed to express TAg under the
control of the -luteinizing hormone promoter, but instead
developed completely penetrant, heritable retinoblastoma
(TAg-RB). Like human retinoblastoma, TAg-RB tumors contain
Homer-Wright rosettes and are the only murine retinoblastoma
tumors reported to also show Flexner-Wintersteiner rosettes.11
The presence of both types of rosette is a hallmark of human
retinoblastoma.12 Because of its high penetrance and histo-
logic11,13 and molecular similarity14–17 to human retinoblas-
toma, this model has been frequently used by several groups to
test retinoblastoma chemotherapies. In fact, approximately 20
studies using this mouse have been published in the past five
years alone, spanning drug testing,18–27 imaging,28–30 and ba-
From the 1Division of Applied Molecular Oncology, Ontario Can-
cer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada;
3Eugene and Marilyn Glick Eye Institute, Department of Ophthalmol-
ogy, and 4Department of Biochemistry and Molecular Biology, Indiana
University School of Medicine, Indianapolis, Indiana; Departments of
5Molecular and Medical Genetics and 8Medical Biophysics, University
of Toronto, Toronto, Ontario, Canada; and the 6Vision Science Re-
search Program, Toronto Western Research Institute, Toronto, On-
tario, Canada.
2These authors contributed equally to the work presented here
and should therefore be regarded as equivalent authors.
7Present affiliation: Department of Ophthalmology and Visual
Sciences, University of Toronto, Toronto, Ontario; and Division of
Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario.
Supported by National Institutes of Health/National Cancer Insti-
tute Grant R01CA118830.
Submitted for publication June 3, 2011; revised July 13, 2011;
accepted August 10, 2011.
Disclosure: S. Pajovic, None; T.W. Corson, None; C. Spencer,
None; H. Dimaras, None; M. Orlic-Milacic, None; M.N. Marchong,
None; K.-H. To, None; B. The´riault, None; M. Auspitz, None; B.L.
Gallie, None
Corresponding author: Brenda L. Gallie, Ontario Cancer Institute/
Princess Margaret Hospital, Division of Applied Molecular Oncology,
610 University Avenue, Toronto, ON, Canada M5G 2M9;
gallie@attglobal.net.
Retinal Cell Biology
Investigative Ophthalmology & Visual Science, September 2011, Vol. 52, No. 10
7618 Copyright 2011 The Association for Research in Vision and Ophthalmology, Inc.
sic tumor biology.14,16,31–34 However, the origin of TAg-RB
tumors has not been characterized beyond the discovery that
they arise within the inner nuclear layer (INL) of the retina.11
Less than 1% of TAg-RB tumor cells display markers of stem
cells or progenitors, such as ALDH1, SCA-1 and p63.35
Here, we have used TAg protein expression in the retina to
track tumor development from the earliest stages. We show
that the cell of origin belongs to a subpopulation of progenitor-




Wild type and TAg-RB mice11 (a gift from the laboratory of Joan
O’Brien) were maintained on a pure C57/B6 background and studied
using protocols approved by the Animal Care Committee of the On-
tario Cancer Institute, in accordance with the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research. Timed pregnancies
were determined by vaginal plug observation, with midday of plug
observation counted as embryonic day (E)0.5.
Bromodeoxyuridine Incorporation Assay
Animals were injected (1 mL reagent per 100 g body weight) with
bromodeoxyuridine (BrdU) reagent (Zymed, San Francisco, CA) and
killed after 2 hours.
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded (FFPE) sections (5 m) of whole
embryos, neonates, or adult TAg-RB eyes were studied. For antigen
retrieval, sections were treated with 0.1% trypsin for 30 minutes or
heated in PBS citrate for 5 minutes in a pressure cooker, followed by
30 minutes in blocking solution (DAKO, Glostrup, Denmark), over-
night incubation with primary antibody (Table 1) and 1-hour incuba-
tion with biotin-labeled secondary antibody (1:200, Vector Labs, Burl-
ington, ON, Canada). Immunoreactivity was detected using a substrate
kit (ImmunoPure Fab Preparation kit; Pierce, Rockford, IL) and/or
fluorescent detection with streptavidin linked to Alexa 488 or Alexa
594. Staining was observed with a microscope (DMLB; Leica, Concord,
ON, Canada) and images recorded using a high-resolution camera
(CoolSNAP; Photometrics, Tucson, AZ). For double-label experiments,
images were superimposed using image-manipulation software (Pho-
toshop; Adobe, San Jose, CA).
RNA Analysis
Total RNA was isolated from wild type C57/B6 mouse retinas and
TAg-RB tumors using reagent (TRIzol; Invitrogen, Burlington, ON, Can-
ada), and first-strand synthesis performed with reverse transcriptase (Su-
perScript II; Invitrogen) according to manufacturer’s protocols. Sequence
detection (TaqMan qRT-PCR) was performed using gene expression as-
says forKif14 (Mm01291391_ml),Hprt (Mm00446968_ml) and reference
Tbp (Mm00446973_ml). All reactions were performed in triplicate (Taq-
Man Master Mix in a 12.5 L volume in a 384-well plate in an SDS 7900H;
Applied Biosystems, Foster City, CA). Raw PCR cycle number required to
reach a fluorescence threshold (Ct), Ct, and Ct were calculated using
commercial software (SDS 2.0; Applied Biosystems).
DNA Analysis
Genomic DNA was isolated from 30 TAg-RB tumors and mouse liver
(normal control) using a proteinase K and phenol-chloroform extrac-
tion method. Semi-quantitative PCR was performed using 50 ng of DNA
and polymerase (KOD DNA polymerase; Novagen, San Diego, CA).
Reactions were performed for 28 cycles using two primer pairs for
each gene: Tbp 5 (forward: gccttacggcacaggactta; reverse: tgtgtgggtt-
gctgagatgt), Tbp 3 (forward: ccccacaactcttccattct; reverse: tggtgtg-
gcaggagtgatag), Cdh11 5 (forward: acattcatgccaccaagaca; reverse: cag-
gcacattggcatgatag), Cdh11 3 (forward: ctgaagccttcgacatagcc;
reverse: tcgtccacatccacactgtt), Dek 5 (forward: ccctcatc-
cgagaaggaac; reverse: ttttcttcctcctcgtcctct), Dek 3 (forward: agtct-
gaatctgaagacagtt; reverse: ctctttgcaaatctgcttcat), E2f3 5 (forward:
ggcacgtacatccagatcct; reverse: gactctgctggagggtcctt), E2f3 3 (for-
ward: agggcccattgaggtttact; reverse: gaagtgggcttgggatatt), Kif14 5
(forward: ctgaccgagagcaagtctga, reverse: atgccttggtgtccatctgt),
Kif14 3 (forward: ggatgctgttcggatatttca; reverse: tgggtactggagacttt-
gctg), Mycn 5 (forward: cctcactcctaatccggtca; reverse: gtggccgtgct-
gtagttttt), Mycn 3 (forward: gttccagcaaaagcgaagag, reverse: gc-
cttctcgttcttcaccag). PCR products were visualized on agarose gels and
band intensity was analyzed using ImageJ software (developed by
Wayne Rasband, National Institutes of Health, Bethesda, MD; available
at http://rsbweb.nih.gov/ij/). Mean values for the two primer pairs per
gene were compared with liver (two-copy control) to calculate gain or
loss.
RESULTS
TAg Expression Begins at P8 in the Inner Nuclear
Layer of TAg-RB Retina
We followed the expression pattern of TAg protein in the
developing retina of TAg-RB mice by immunohistochemistry
(Fig. 1A). TAg expression was first observed in the nuclei of
sparse cells within the INL at P8. At P12, an increased number
of TAg-positive cells formed a single row of cells in the center
of the INL. At P21, TAg-positive cells occupied much of the
INL, after which numbers of single cells declined and clusters
TABLE 1. Antibodies Used for Immunohistochemistry
Antibody Marker for Source Dilution
SV40 TAg TAg-RB Santa Cruz, Santa Cruz, CA 1:200
Activated Caspase 3 Apoptosis R&D Systems, Minneapolis, MN 1:50
BrdU Proliferation BD Biosciences, Mississauga, ON, Canada 1:500
TuJ1 Early neurons Stemcell Technologies, Vancouver, BC, Canada 1:50
Ki-67 Proliferation Lab Vision, Fremont, CA 1:200
HPC-1 Amacrine cells Sigma, Oakville, ON, Canada 1:100
NEFM Horizontal cells Sigma 1:40
Chx10 Progenitors/Mu¨ller subpopulation Bremner laboratory9 1:2000
CRALBP Mu¨ller glia Saari laboratory9 1:1000
PKC Bipolar cells BD Biosciences 1:50
Gln synthetase Mature Mu¨ller glia Santa Cruz 1:200
Car2 Mature Mu¨ller glia Novus, Oakville, ON, Canada 1:50
Clusterin Mature Mu¨ller glia Santa Cruz 1:100
p75NTR Lost in retinoblastoma Chemicon, Temecula, CA 1:200
DEK Gained in retinoblastoma BD Biosciences 1:200
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of TAg-positive cells were observed at P28. At P35, multiple
large tumor foci were observed. The reduction in TAg-express-
ing cells from P21 to P28 prompted us to examine whether this
decline was due to cell death rather than loss of TAg expres-
sion. We double-stained P21 TAg-RB retina for the presence of
activated caspase-3 and TAg (Fig. 1B). The majority of TAg-
positive cells expressed activated caspase-3 at P21, suggestive
of widespread apoptosis.
TAg-RB Cells Express Proliferation Markers
Retinal cells from P8 and P9 wild type mice were rarely posi-
tive for proliferation markers Ki-67 (stains cells in G1, S, G2, and
M phases) or incorporated BrdU (incorporated into DNA dur-
ing S phase), suggesting that cells had already undergone or
were in the process of undergoing terminal mitosis (data not
shown). However, in the TAg-RB littermates of these animals,
Ki-67 expression and BrdU incorporation were observed in a
subset of TAg-positive cells (Fig. 2). At most time points, we
observed similar regions of staining for BrdU and TAg, suggest-
ing that the cells in S-phase at the time of BrdU exposure
expressed TAg. Interestingly, at P9 and P12 we observed cells
that were positive for Ki-67 but not for TAg expression (Fig. 2).
TAg-Expressing Cells Are Negative for Neuronal
Marker TuJ1
To determine whether TAg-expressing cells display neuronal
properties, we double stained TAg-RB retinas for TAg and TuJ1,
a marker of early neuronal development that is absent in
differentiated glia.36,37 TAg-expressing cells were negative for
TuJ1 at both early (Fig. 3) and late (data not shown) stages of
tumor development.
TAg-Positive Cells Express Markers of Mature
Mu¨ller Glia
To investigate whether TAg-positive cells represent a distinct
retinal cell type, we performed double immunostaining for
TAg and individual markers of the cells that compose the INL
of the mature retina (Table 1). We studied both the initiating
stages of tumor development (P8, P9) to assess the cell of
origin before TAg transformation could potentially affect gene
expression of the cell, and later stages (P12, P21, P29) during
tumorigenesis.
At P8 and P9, TAg expression overlapped with CRALBP
(Mu¨ller glia), and Chx10 (bipolar cells and a subpopulation of
mature Mu¨ller glia), clusterin (mature Mu¨ller glia38), carbonic
anhydrase II (mature Mu¨ller glia38), and glutamine synthetase
FIGURE 1. Distinct pattern of TAg expression in the TAg-RB develop-
ing retina. (A) Immunohistochemical analysis shows expression of TAg
(red) in developing retina from postnatal day (P)5 to P35. Expression
of TAg started in single cells at P8, localized to the inner nuclear layer
(original magnification, 400). (B) Expression of activated caspase
3 (green) and TAg (red) at P21, low (200) (left) and high (400)
(right) magnification. The majority of cells expressed both proteins;
rare cells expressed TAg only (arrow).
FIGURE 2. Expression of proliferation markers in the course of TAg-RB
development. Adjacent retinal sections from mice injected with BrdU
were immunostained for BrdU (brown), TAg (green), or Ki-67 (red).
Although the majority of the cells that were proliferating (BrdU or
Ki-67 positive) were TAg-positive, there were a number of cells that
showed proliferation marker or TAg expression only. Original magni-
fication, 400.
FIGURE 3. TAg expressing cells do not express neuronal marker TuJ1.
There was no expression of TuJ1 (green) in TAg (red) positive cells at
P9 and P12, suggesting a nonneuronal origin of these cells. Original
magnification, 1000.
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(mature Mu¨ller glia38), but not with HPC-1 (amacrine cells),
neurofilament 160 kDa (Nefm) (horizontal cells) or PKC (bipo-
lar cells39) (Figures 4, 5, and 6). The same pattern was ob-
served in the later stages of development, except that CRALBP
was absent from TAg-positive cells at P29 and TAg-RB tumors
(Fig. 4), and clusterin staining in large tumors was inconclusive
(data not shown).
Cells positive for both TAg and Chx10 showed less intense
Chx10 staining than cells that were positive for only Chx10
(Fig. 4). The double-stained population was confined to a
distinct location within the INL, different from the more in-
tensely stained Chx10 population at the external edge of the
INL where bipolar cells are normally found. At P9 and P12 the
TAg positive cells were negative for PKC, a marker of mature
bipolar cells (Fig. 5).
TAg-RB Tumors Express
Retinoblastoma-Associated Tumor Suppressor
Genes during Initiation, and Overexpress
Oncogenes during Progression of Tumorigenesis
We have identified a number of genes involved in the progres-
sion of human retinoblastoma after loss of RB1.14–16,40,41 We
evaluated their role in the TAg-RB model by measuring gene
copy number for Cdh11, Mycn, Kif14, E2f3, and Dek in
TAg-RB tumors compared with the liver control using semi-
quantitative PCR (Fig. 7A). Loss of Cdh11 occurred in 45% of
TAg-RB tumors. Gain in copy number was evident in TAg-RB
tumors for Kif14 (33%), Mycn (19%), and E2f3 (18%). Kif14
genomic gain was reinforced at the expression level: Kif14
mRNA was higher in 9 of 11 large tumors than at any point in
normal retinal development (Fig. 7B).
Early expression of TAg in single cells at P9 coincided with
expression of tumor suppressor genes p75NTR and Cdh11, and
oncogenes Dek and E2f3 (Fig. 7C and data not shown). Expres-
sion of E2f3 and Dek remained high throughout tumor devel-
opment. We have previously shown that expression of the
tumor suppressor genes p75NTR and Cdh11 is lost from pro-
gressing large tumors starting at P28.14,15
DISCUSSION
The Value of the TAg-RB Model
The TAg-RB tumors have striking histologic and molecular
similarity to human retinoblastoma, including focal initiation,
lost expression of tumor suppressor genes Cdh1115 and
p75NTR,14 overexpression of oncogenes DEK and E2F316 and
presence of Homer-Wright and Flexner-Wintersteiner ro-
settes.11 Approximately 20 different mouse models have been
created in an attempt to recapitulate human retinoblastoma
(reviewed in Ref. 42), however TAg-RB has the closest histo-
logic resemblance to human tumors. In addition, most other
models do not recreate the sporadic nature of human RB1
mutation in a susceptible retinal cell. The TAg-RB model
achieves this by inactivating pRB and related proteins in spe-
cific cells in the context of an otherwise normal retina.
The functional consequences of TAg expression depend on
the cell type and context in which it is expressed; for example,
TAg can cause degeneration43,44 or tumor formation43 in pho-
toreceptors and apoptosis in horizontal cells.45 Thus, the ex-
pression of TAg in mature neurons does not necessarily lead to
oncogenesis. In TAg-RB, TAg expression is governed by an
unknown, retinal-specific genomic element that directs expres-
sion of TAg to only one cellular population during a narrow
window of time during development. Identifying this popula-
tion was a major goal of the current work.
Regulation of TAg Expression in TAg-RB Mice
Because the expression of TAg was restricted to the INL at all
time points studied (Fig. 1), an INL origin of the tumors is
certain. TAg expression was tightly regulated developmentally,
beginning with only a few TAg-positive cells at P8 and gradu-
ally expanding by P13. Active proliferation and the initial
steady increase in numbers of TAg-RB cells (Fig. 1) suggest that
when TAg is expressed, this trait is maintained in the TAg-
expressing lineage. Although at P9, early TAg-expressing cells
expressed CRALBP (Fig. 4), later TAg-positive cells and pro-
gressing tumors did not express this glial marker.
The majority of TAg-expressing cells also expressed the
apoptotic signaling molecule p75NTR 14 and activated caspase-3
(Fig. 1B) at P21, suggesting that the expression of TAg results
in the activation of cell death, accounting for the decrease in
TAg-expressing cell number, as we suggested previously.14
Occasional TAg-expressing cells escaped cell death (Fig. 1B,
arrow) and formed clusters of early tumors by P28. This
defined, clonal regulation of tumor initiation and development,
together with complete disease penetrance and retinoblasto-
ma-like histology, justifies the use of the TAg-RB model to test
therapies.
FIGURE 5. Cells expressing TAg are not mature bipolar cells. Mature
bipolar marker PKC (green) showed no overlap with TAg (red) ex-
pression. Original magnification, 1000.
FIGURE 4. Expression of TAg overlaps with expression of Mu¨ller glial
markers. Expression of all major retinal cell type markers (green) and
TAg (red) from P9 to P29. No overlap was found for HPC-1 (amacrine
cells), or neurofilament 160 kDa (Nefm) (horizontal cells) and com-
plete overlap at all time points was found for Chx10 (retinal progeni-
tors and bipolar cells). Coexpression of CRALBP (Mu¨ller glia) and TAg
was found only at the very early time point (P9) and by P12, the
majority of TAg-positive cells did not express CRALBP. Original mag-
nification, 1000.
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The Cell of Retinoblastoma Origin
The cell of retinoblastoma origin is being actively sought (re-
viewed in Ref. 46). Its identity has been inferred by examining
expression of markers of retinal cell type and developmental
stage (precursor/stem cell, mature/differentiated) within
pathologic specimens of human retinoblastoma. Rod- and
cone-specific genes are expressed most frequently, interpreted
to indicate that retinoblastoma originates in photorecep-
tors,47,48 consistent with the presence of rosettes with histo-
logic similarities to photoreceptor outer segments.49,50 Other
studies, however, show that retinoblastoma tumors express
many other cell type markers, including Mu¨ller glia, amacrine,
and ganglion cell markers.51,52 To our knowledge, the expres-
sion of only one neuronal stem cell marker, MCM2, has been
demonstrated in human retinoblastoma, however its expres-
sion was mainly restricted to tumor adjacent to blood vessels.35
Although clinical retinoblastoma specimens are invaluable for
such studies, they are usually large, advanced tumors necessi-
tating enucleation (retinoblastoma diagnosed early in its devel-
opment can be successfully treated without enucleation), and
often display promiscuous expression of various cell type
markers.
Mouse models that use genetic inactivation of Rb1 in com-
bination with p107 or p130 loss7,9 develop tumors emerging
from the INL that express amacrine and glial cell markers,
consistent with observations of the early pRB/p107-deficient
chimeric retinoblastoma model.8 As in human retinoblastoma,
marker expression in late-stage tumors is promiscuous. TAg is
an unambiguous marker of TAg-RB tumor cells, enabling us to
follow and analyze characteristics of the cell of origin from the
onset of tumor initiation, before transformation could poten-
tially corrupt the normal patterns of gene expression.
The TAg-RB Cell of Origin
We show that the TAg-RB cell of origin displays characteristics
of mature Mu¨ller glia (Figures 4, 5, and 6). Although gene
expression in Mu¨ller glia is very similar to that observed in
retinal progenitors,38 expression of Mu¨ller glial-specific clus-
terin and carbonic anhydrase II38 in TAg-expressing cells pro-
vides definitive evidence of a Mu¨ller glial origin for these cells.
The absence of expression of the early neuronal marker TuJ1
(Fig. 3) suggests that the TAg-RB cell of origin is not an early
progenitor cell (Fig. 2).
TAg-positive Mu¨ller glia expressed Chx10 at a low level
from their first emergence at P9 throughout transformation
(Fig. 4). This expression was lower in the TAg-expressing cells
than in neighboring mature bipolar cells. A subpopulation of
postmitotic Mu¨ller glia that expresses Chx10 has been identi-
fied and proposed as more progenitor-like than non–Chx10-
expressing Mu¨ller glia.53 Alternatively, it has been proposed
that all Mu¨ller glia retain neural stem cell properties, and are
capable of reversing their differentiation.54 The TAg expres-
sion in Chx10-positive cells from the earliest time point studied
(P8) is consistent with the cell of origin of the TAg-RB tumors
being such Chx10-expressing Mu¨ller glia with the capacity of
progenitors. TAg could also directly inactivate transcription
factors to alter the expression of retinal cell type markers.
We propose that the TAg-RB cell of origin is a sparse,
Chx10-expressing differentiated Mu¨ller glial cell that is ex-
tremely sensitive to TAg oncogenic insult because of its dor-
mant progenitor capabilities. The combination of strong onco-
genic stimulation by TAg and the progenitor characteristics of
this cell may reduce the minimum number of post-Rb1 loss
events needed to achieve malignant transformation. In fully
differentiated brain neurons without progenitor features, con-
FIGURE 6. Late Mu¨ller cell type mark-
ers are expressed in TAg positive cells.
(A) A subset of cells expressing three
markers of mature Mu¨ller cells (glu-
tamine synthetase, carbonic anhydrase II
[Car2], and clusterin) (green) expressed
TAg (red) at P9. (B) Tumors in TAg ret-
inas expressed TAg and retained the ex-
pression of Car2. Original magnification,
1000.
FIGURE 7. Post-Rb1 mutation geno-
mic changes in TAg-RB. (A) TAg-RB
showed copy number variation for four
of five gene candidates tested: Cdh11,
Mycn,Kif14, andE2f3. (B)Kif14mRNA
is overexpressed in TAg-RB compared
with developing or adult (A) retina.Hprt
was used as an endogenous control. (C)
Expression of p75NTR (green) and Dek
(green) was confirmed in TAg-express-
ing (red) cells at P9. Original magnifica-
tion, 1000.
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tinuous overexpression of TAg stimulates cell cycle re-entry55
followed by cellular degeneration.56
Evasion of Apoptosis and Promotion of
TAg-RB Tumorigenesis
The TAg- and Chx10-positive cells proliferated within the INL
of the retina, and by P21 expressed activated caspase-3 (Fig.
1B). We showed previously that the TAg-expressing cells are
p75NTR-positive at P21 and display pyknotic nuclei, indicative
of apoptosis.14 Cells that lose expression of p75NTR escape
apoptosis and give rise to tumors. By P28, TAg was restricted
to foci from which tumors emerge. The activation of apoptosis
days after initial TAg expression suggests that a few rounds of
uncontrolled proliferation occur without activation of an apo-
ptotic pathway. It has been suggested that the human retino-
blastoma cell of origin evades apoptosis by functional inactiva-
tion of p53, either by increased MDM257 and/or MDM458 or
posttranscriptional inactivation of p14ARF.59 Because p53 is
inactivated by TAg in our model, we could not assess this in
our study.
The eventual TAg-RB tumors arose from the less common
cells that escape apoptosis. The time delay between initial TAg
expression and eventual tumor formation implies the need for
the accumulation of other mutations for complete malignant
transformation. Indeed, we found that several genomic
changes characteristic of human retinoblastoma14–16,40,41
were also evident in TAg-RB at both the genomic and expres-
sion levels (Fig. 7). Our findings complement a recent microar-
ray study of TAg-RB tumors that demonstrates overlap with
some genes (including KIF14) found to be dysregulated in
human retinoblastoma.17 The post-RB1 loss genetic changes
common to the TAg-RB tumors and human retinoblastoma
confirms their universal role in retinoblastoma progression in a
susceptible retinal cell irrespective of the mechanism of RB1
family inactivation. It will be interesting to examine these
changes in other murine retinal tumor models.
We identify the developing retinal cell with features of
progenitor-like Mu¨ller glia, in which TAg is expressed in the
TAg-RB model. This cell is induced by TAg to die, or escapes
death by acquiring secondary genomic and gene expression
changes similar to those found in human retinoblastoma, that
result in murine retinoblastoma. TAg-RB is thus a good model
of human retinoblastoma that recapitulates both molecular and
histologic features of the human disease, supporting its use to
study therapies for early and late stages of retinoblastoma.
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